These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37762058)

  • 1. A Multiplexed Urinary Biomarker Panel Has Potential for Alzheimer's Disease Diagnosis Using Targeted Proteomics and Machine Learning.
    Hällqvist J; Pinto RC; Heywood WE; Cordey J; Foulkes AJM; Slattery CF; Leckey CA; Murphy EC; Zetterberg H; Schott JM; Mills K; Paterson RW
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning.
    Wang Y; Sun Y; Wang Y; Jia S; Qiao Y; Zhou Z; Shao W; Zhang X; Guo J; Zhang B; Niu X; Wang Y; Peng D
    Alzheimers Res Ther; 2023 Nov; 15(1):191. PubMed ID: 37925455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics.
    Gaetani L; Bellomo G; Parnetti L; Blennow K; Zetterberg H; Di Filippo M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis of Alzheimer's Disease Using Quantitative Mass Spectrometry of Human Blood Plasma Proteins and Machine Learning.
    Kononikhin AS; Zakharova NV; Semenov SD; Bugrova AE; Brzhozovskiy AG; Indeykina MI; Fedorova YB; Kolykhalov IV; Strelnikova PA; Ikonnikova AY; Gryadunov DA; Gavrilova SI; Nikolaev EN
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma.
    Khan MJ; Desaire H; Lopez OL; Kamboh MI; Robinson RAS
    J Alzheimers Dis; 2021; 79(3):1327-1344. PubMed ID: 33427747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.
    Wildsmith KR; Schauer SP; Smith AM; Arnott D; Zhu Y; Haznedar J; Kaur S; Mathews WR; Honigberg LA
    Mol Neurodegener; 2014 Jun; 9():22. PubMed ID: 24902845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF.
    Spellman DS; Wildsmith KR; Honigberg LA; Tuefferd M; Baker D; Raghavan N; Nairn AC; Croteau P; Schirm M; Allard R; Lamontagne J; Chelsky D; Hoffmann S; Potter WZ; ;
    Proteomics Clin Appl; 2015 Aug; 9(7-8):715-31. PubMed ID: 25676562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
    Heywood WE; Galimberti D; Bliss E; Sirka E; Paterson RW; Magdalinou NK; Carecchio M; Reid E; Heslegrave A; Fenoglio C; Scarpini E; Schott JM; Fox NC; Hardy J; Bhatia K; Heales S; Sebire NJ; Zetterberg H; Mills K
    Mol Neurodegener; 2015 Dec; 10():64. PubMed ID: 26627638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.
    Wisch JK; Butt OH; Gordon BA; Schindler SE; Fagan AM; Henson RL; Yang C; Boerwinkle AH; Benzinger TLS; Holtzman DM; Morris JC; Cruchaga C; Ances BM
    Brain; 2023 Jul; 146(7):2944-2956. PubMed ID: 36542469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
    Jiang Y; Zhou X; Ip FC; Chan P; Chen Y; Lai NCH; Cheung K; Lo RMN; Tong EPS; Wong BWY; Chan ALT; Mok VCT; Kwok TCY; Mok KY; Hardy J; Zetterberg H; Fu AKY; Ip NY
    Alzheimers Dement; 2022 Jan; 18(1):88-102. PubMed ID: 34032364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
    Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J
    J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.
    Korecka M; Shaw LM
    J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Candidate Biomarkers of Alzheimer's Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics.
    Liu P; Li L; He F; Meng F; Liu X; Su Y; Su X; Luo B; Peng G
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics.
    Weiner S; Blennow K; Zetterberg H; Gobom J
    Expert Rev Proteomics; 2023; 20(7-9):143-150. PubMed ID: 37701966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and prognosis of Alzheimer's disease using brain morphometry and white matter connectomes.
    Wang Y; Xu C; Park JH; Lee S; Stern Y; Yoo S; Kim JH; Kim HS; Cha J;
    Neuroimage Clin; 2019; 23():101859. PubMed ID: 31150957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposing the Brain Proteomic Signatures of Alzheimer's Disease in Diverse Racial Groups: Leveraging Multiple Data Sets and Machine Learning.
    Desaire H; Stepler KE; Robinson RAS
    J Proteome Res; 2022 Apr; 21(4):1095-1104. PubMed ID: 35276041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
    Robinson RA; Amin B; Guest PC
    Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.
    Vafadar-Isfahani B; Ball G; Coveney C; Lemetre C; Boocock D; Minthon L; Hansson O; Miles AK; Janciauskiene SM; Warden D; Smith AD; Wilcock G; Kalsheker N; Rees R; Matharoo-Ball B; Morgan K
    J Alzheimers Dis; 2012; 28(3):625-36. PubMed ID: 22045497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.